07/03/2019 16:52:39

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, TYME, VNDA and CVS

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. 

Maxar Technologies Inc. (NYSE: MAXR)

Class Period: March 29, 2018 to January 7, 2019

Lead Plaintiff Deadline: March 15, 2019

The complaint alleges that during the class period Maxar Technologies Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

Get additional information about the MAXR lawsuit: https://www.kleinstocklaw.com/pslra-1/maxar-technologies-inc-loss-submission-form?wire=3

Tyme Technologies, Inc. (NASDAQCM: TYME)

Class Period: March 14, 2018 to January 18, 2019

Lead Plaintiff Deadline: March 29, 2019

The complaint alleges Tyme Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

Get additional information about the TYME lawsuit: https://www.kleinstocklaw.com/pslra-1/tyme-technologies-inc-loss-submission-form?wire=3

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)

Class Period: November 4, 2015 to February 11, 2019

Lead Plaintiff Deadline: April 26, 2019

During the class period, Vanda Pharmaceuticals Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the VNDA lawsuit: https://www.kleinstocklaw.com/pslra-1/vanda-pharmaceuticals-inc-loss-submission-form?wire=3

CVS Health Corporation (NYSE: CVS)

Class Period: May 21, 2015 to February 20, 2019

Lead Plaintiff Deadline: April 26, 2019

Throughout the class period, CVS Health Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) CVS Health’s financial condition and expected earnings were deteriorating as a result of rising costs and poor results associated with the Omnicare Acquisition; and (ii) as a result, CVS Health’s public statements were materially false and misleading at all relevant times.

Get additional information about the CVS lawsuit: https://www.kleinstocklaw.com/pslra-1/cvs-health-corporation-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

Klein NEW logo black transparent.png

Related content
18 Mar - 
Deadline Reminder: The Law Offices of Howard G. Smith R..
18 Mar - 
The Klein Law Firm Reminds Investors of Class Actions o..
17 Mar - 
CLASS ACTION UPDATE for GSM, WRCDF, CAG and VNDA: Levi ..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
HPV Vaccine Mandate Ill-Advised, States Association of American Physicians and Surgeons (AAPS)
2
AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
3
Jumio Partners with ComplyAdvantage to Reduce AML Risk Exposure
4
Global Gaming’s X2 Games Announces the Launch of Pre-Orders for its Cutting-Edge Amazon Alexa Powered Board Game St. Noire
5
BOXX Showcases Data Science Workstation and Other Solutions at GTC

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 March 2019 10:46:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB3 - 2019-03-19 11:46:31 - 2019-03-19 10:46:31 - 1000 - Website: OKAY